Friday's Health Winners & Losers

Par also announced today that its board approved an expansion of its share-repurchase program of up to $75 million of the company's common stock. Shares rolled down $3.07, or 14%, to $18.61.

Elsewhere, Isis Pharmaceuticals(ISIS Quote) said after the market close Thursday it purchased all of the equity of Symphony GenIsis for $120 million. Earlier in the month, Isis announced that it would do so before closing a metabolic-disease focused collaboration with Johnson & Johnson's(JNJ Quote) Ortho-McNeil. Isis was down 2.5% at $14.97.

And some stocks moved on legal news. Pfizer(PFE Quote) said today that the Canadian Federal Court in Toronto ruled that its second medical use patent covering Viagra would be infringed by Apotex's proposed generic product and granted the company's application for an order preventing Apotex from launching a generic version of Viagra until expiration of Canadian Patent No. 2,163,446 in 2014. The decision is subject to appeal. Nonetheless, Pfizer edged down 32 cents, or 1.4%, to $24.43.

Also, Bristol-Myers Squibb(BMY Quote) announced Friday that it finalized a civil settlement agreement with the Department of Justice and the U.S. Attorney for the District of Massachusetts, wrapping up previously disclosed investigations beginning several years ago with regard to pricing and sales and marketing activities. The company entered a five-year corporate integrity agreement and will pay a previously announced $499 million in civil resolution. Shares were down just 19 cents, or 0.7%, to $28.82.